Antitumor effect of degalactosylated gc-globulin on orthotopic grafted lung cancer in mice.

BACKGROUND Group-specific component (Gc)-globulin-derived macrophage-activating factor (GcMAF) generated by a cascade of catalytic reactions with deglycosidase enzymes exerts antitumor activity. We hypothesized that degalactosyl Gc-globulin (DG3), a precursor of GcMAF, also plays a role in recovery from cancer as well as GcMAF due to progression of deglycosylation by generally resident sialidases and mannosidases. MATERIALS AND METHODS We prepared the subtypes of DG3, such as 1f1f and 1s1s and its 22 homodimers, by using vitamin D3-binding Sepharose CL-6B and examined their antitumor activity in mice bearing Lewis lung carcinoma cells, by counting the number of nodules formed in their lungs. RESULTS Antitumor activity of DG3 was observed regardless of its subtype, being equivalent to that of GcMAF. The injection route of DG3 affected its antitumor activity, with subcutaneous and intramuscular administration being more favorable than the intraperitoneal or intravenous route. In order to obtain significant antitumor activity, more than 160 ng/kg of DG3 were required. CONCLUSION DG3 proved to be promising as an antitumor agent, similarly to GcMAF.

[1]  H. Terada,et al.  β-Galactosidase treatment is a common first-stage modification of the three major subtypes of Gc protein to GcMAF. , 2012, Anticancer research.

[2]  H. Terada,et al.  Effect of the Gc-derived macrophage-activating factor precursor (preGcMAF) on phagocytic activation of mouse peritoneal macrophages. , 2011, Anticancer research.

[3]  S. Dridi,et al.  Vitamin D Binding Protein-Macrophage Activating Factor Directly Inhibits Proliferation, Migration, and uPAR Expression of Prostate Cancer Cells , 2010, PloS one.

[4]  R. Heaney,et al.  Vitamin D3 Distribution and Status in the Body , 2009, Journal of the American College of Nutrition.

[5]  N. Yamamoto,et al.  Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF. , 2008, Translational oncology.

[6]  N. Yamamoto,et al.  Retracted: Immunotherapy of metastatic breast cancer patients with vitamin D‐binding protein‐derived macrophage activating factor (GcMAF) , 2008, International journal of cancer.

[7]  N. Yamamoto,et al.  RETRACTED ARTICLE: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF , 2008, Cancer Immunology, Immunotherapy.

[8]  S. Nagai,et al.  Applications of lipopolysaccharide derived from Pantoea agglomerans (IP-PA1) for health care based on macrophage network theory. , 2006, Journal of bioscience and bioengineering.

[9]  F. Lammert,et al.  Gc-globulin: Roles in Response to Injury , 2005 .

[10]  N. Swamy,et al.  Inhibition of angiogenesis by vitamin D-binding protein: Characterization of anti-endothelial activity of DBP-maf , 2006, Angiogenesis.

[11]  H. Nagasawa,et al.  Association of the macrophage activating factor (MAF) precursor activity with polymorphism in vitamin D-binding protein. , 2004, Anticancer research.

[12]  H. Nagasawa,et al.  Gc protein-derived macrophage activating factor (GcMAF): isoelectric focusing pattern and tumoricidal activity. , 2003, Anticancer research.

[13]  R. D'Amato,et al.  Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. , 2003, Neoplasia.

[14]  P. Vestergaard,et al.  Mean serum concentration of vitamin D-binding protein (Gc globulin) is related to the Gc phenotype in women. , 2001, Clinical chemistry.

[15]  R. Tauber,et al.  Characterization of a soluble class I α‐mannosidase in human serum , 1999 .

[16]  N. Yamamoto,et al.  Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. , 1997, Cancer research.

[17]  S. Asbell,et al.  Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. , 1996, Cancer research.

[18]  N. Yamamoto,et al.  Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[19]  N. Cooke,et al.  The vitamin D-binding protein, alpha-fetoprotein, albumin multigene family: detection of transcripts in multiple tissues. , 1989, The Journal of biological chemistry.

[20]  J. Haddad,et al.  Interactions among serum vitamin D binding protein, monomeric actin, profilin, and profilactin. , 1989, The Journal of biological chemistry.

[21]  S. Tsuiki,et al.  Cytosolic sialidases of rat tissues with special reference to skeletal muscle enzyme. , 1986, Biochemistry International.

[22]  H. DeLuca,et al.  Purification of human serum vitamin D-binding protein by 25-hydroxyvitamin D3-Sepharose chromatography. , 1986, Analytical biochemistry.

[23]  B. Bowman,et al.  Post-translational heterogeneity of the human vitamin D-binding protein (group-specific component). , 1983, Archives of biochemistry and biophysics.

[24]  A. Kurosky,et al.  Molecular basis for the three major forms of human serum vitamin D binding protein (group-specific component). , 1979, Biochemistry.

[25]  L. Cavalli-Sforza,et al.  Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[26]  L. Warren,et al.  Mammalian sialidase (neuraminidase). , 1960, Biochemical and biophysical research communications.